Foresite Capital

Portfolio Co Investors 2026 for Foresite Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Foresite Capital accounts for 55 tracked companies with verified cap-table data, 55 of which disclose round sizes totalling $12B. The median disclosed raise is $160M, and the largest is Kriya Therapeutics at $1.2B, ahead of Cue ($606M) and Alumis ($529M).

The names that recur most often on these co-invested cap tables are Foresite Capital (55 companies), OrbiMed (9 companies), Janus Henderson Investors (8 companies), RA Capital Management (7 companies), Decheng Capital (6 companies), Logos Capital (6 companies). By latest disclosed round, the market skews Series C (16), Series B (15), Series A (13), Series D (5).

Best funded Foresite Capital companies

  1. Kriya Therapeutics — $1.2B (latest: Series C)
  2. Cue — $606M (latest: Series C)
  3. Alumis — $529M (latest: Series C)
  4. DNAnexus — $473M (latest: Series H)
  5. Mammoth Biosciences — $465M (latest: Series D)
  6. Avenzo Therapeutics — $446M (latest: Series A)
  7. Delfi Diagnostics — $400M (latest: Series B)
  8. Candid Therapeutics — $370M (latest: Series A)
  9. Affinivax — $359M (latest: Series C)
  10. Decibel Therapeutics — $341M (latest: Series C)
  11. Ollin Biosciences — $330M (latest: Series B)
  12. FogPharma — $323M (latest: Series D)
  13. Crossover Health — $292M (latest: Series D)
  14. Pardes Biosciences — $276M (latest: IPO)
  15. Genapsys Inc. — $250M (latest: Series D)

Foresite Capital — related firms and companies (56)

Foresite Capital profile · All research reports